Kurihara-Hosokawa Kotomi, Kawasaki Isao, Tamai Anna, Yoshida Yoko, Yakushiji Yosuke, Ueno Hiroki, Fukumoto Mariko, Fukushima Hiroko, Inoue Takeshi, Hosoi Masayuki
Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan.
Intern Med. 2014;53(19):2211-4. doi: 10.2169/internalmedicine.53.2546.
We encountered a case of epithelioid inflammatory myofibroblastic sarcoma (EIMS) originating from an abdominal organ that rapidly regrew twice. The patient underwent two surgeries. Large tumors grew within three months after the second surgery. The patient subsequently received chemotherapy with an anaplastic lymphoma kinase (ALK) inhibitor. Although EIMS has a poor prognosis, the patient continues to be alive with disease 14 months after surgical treatment and the administration of the ALK inhibitor.
我们遇到了一例起源于腹部器官的上皮样炎性肌成纤维细胞肉瘤（EIMS），该肿瘤迅速复发了两次。患者接受了两次手术。第二次手术后三个月内出现了巨大肿瘤。患者随后接受了使用间变性淋巴瘤激酶（ALK）抑制剂的化疗。尽管EIMS预后较差，但患者在手术治疗和使用ALK抑制剂后14个月仍带瘤存活。
